Multibagger Selection: Grok 4.5's picks
Grok 4.5 picked INOD, NRIX, IVA, AAPG, BBAI with a twelve-month thesis, measured against SPY at each checkpoint.
| Experiment | Multibagger Selection |
|---|---|
| Model | Grok 4.5 |
| Prompt version | multibagger-selection-v1 |
| Asked | |
| Horizon | 12-month |
| Benchmark | SPY |
| Status | Being measured |
The picks
| Rank | Symbol | Return | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|
| 1 | INOD | — | 72% | — | — |
| 2 | NRIX | — | 68% | — | — |
| 3 | IVA | — | 65% | — | — |
| 4 | AAPG | — | 62% | — | — |
| 5 | BBAI | — | 58% | — | — |
Checkpoints
| Checkpoint | Portfolio return | Return vs SPY | Best peak multiple | Picks reaching 2x |
|---|---|---|---|---|
| 1 week | -2.33% | -1.15% | 1.13x | 0 |
The model's market view
Small- and mid-cap equities in AI infrastructure, data services and clinical-stage biotech show elevated volatility but asymmetric upside potential from specific near-term catalysts amid broader market focus on large-cap tech and rate sensitivity. Liquidity remains adequate in names with average daily dollar volume above $5 million, while valuation dispersion favors companies demonstrating operating leverage or binary clinical readouts within the 12-month window.
Why each pick
INOD
Innodata is converting its data-annotation services franchise into higher-margin proprietary AI platforms and physical-AI datasets, evidenced by 58% year-over-year revenue growth in Q2 2026 to $92.1 million, adjusted gross margin expansion to 49%, and adjusted EBITDA up 92%. Customer diversification is underway while a self-serve data platform and new motion-capture lab for humanoid robotics create incremental high-ROI revenue streams. Consensus and management commentary support continued double-digit growth into 2027 with operating leverage already visible in free-cash-flow generation.
NRIX
Nurix’s targeted protein degradation platform has been validated by a large Roche collaboration on bexobrutideg (BTK degrader) that includes substantial upfront and milestone economics plus 50/50 U.S. profit share. Multiple clinical catalysts in 2026, including Phase 1b/2 combination data and Phase 3 initiation in CLL, provide near-term de-risking points. Cash position of approximately $593 million (4Q25) plus partnership inflows supports multi-year runway without immediate dilutive financing.
IVA
Inventiva’s pan-PPAR agonist lanifibranor is fully enrolled in the Phase 3 NATiV3 trial in MASH with F2/F3 fibrosis; topline results are expected in Q4 2026. Positive data would support NDA submission in H1 2027 and potential U.S. launch in 2028. Cash and short-term deposits of €234 million provide runway through the readout and filing window.
AAPG
Ascentage is transitioning from clinical to commercial stage with olverembatinib sales growing >80% in 2025 and H1 2026 product revenue contributing the majority of the $44.5 million total (+29% YoY). Multiple registrational Phase 3 trials and NDA filings expected in 2026–2027 provide sequential catalysts while gross margins remain high on product sales.
BBAI
BigBear.ai holds a 10-year IDIQ contract vehicle with the U.S. Air Force valued up to $900 million and has recorded sequential backlog growth and multiple new defense and intelligence wins in 2026. Gross margins expanded meaningfully in recent quarters while the company continues to win task orders in mission-critical AI. High trading liquidity supports institutional interest.
Other models on the same run
| Model | Picks |
|---|---|
| Gemini 1.5 Pro | LUNR, SOUN, ENVX, ACHR, SMR |
| Muse Spark 1.1 | EOSE, LUNR, SOUN, TMC, LAC |
| Perplexity | MAZE, EVER, PGY, PENG, SOUN |
| DeepSeek | INOD, AEHR, ASYS, BBAI, HTFL |
| GPT-6 | TSSI, INOD, SEDG, AMPX, LUNR |
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.